

Akhu Therapeutics Licenses Technology to Relieve Depression Faster

Akhu Therapeutics has licensed innovative technology for developing medicine to relieve depression in a fraction of the time required by current therapies.

COLLEGE STATION, TEXAS, USA, April 21, 2016 /EINPresswire.com/ -- Akhu Therapeutics (Akhu) has entered an agreement with the University of Arizona (UA) and Texas A&M University (TAMU). The agreement, facilitated by Tech Launch Arizona, licenses a series of peptide blockers of the melanocortin-5 receptor (MC5R) to Akhu. These state-of-the-art MC5R blockers resulted from the collaborative invention of Caurnel Morgan, PhD while at TAMU, and Minying Cai, PhD and Victor Hruby, PhD at UA.



Akhu Therapeutics

The exclusive, worldwide license enables Akhu to develop these peptides to treat [depression](#) and [anxiety](#). These mental disorders cause major health problems worldwide, and although antidepressants are widely used for both disorders, many users do not respond to them. When relief occurs, it is typically modest, slow to onset, and accompanied by serious side effects. Although anxiolytics provide fast relief from the symptoms of anxiety, they are addictive if taken long-term.

Unfortunately, many depression and anxiety patients require long-term treatment. MC5R blockade differs fundamentally from the actions of antidepressants and anxiolytics. In animal models of depression and anxiety that predict therapeutic efficacy in humans, MC5R blockers are more effective, more potent, and faster acting than antidepressants without side effects thus far.

About Akhu Therapeutics, Inc.

Akhu is a biopharmaceutical startup that is developing medicine to extinguish depression and anxiety, which increase mortality and disability for 350 million people worldwide, particularly women. The therapeutic potential of MC5R blockade in animal models of depression and anxiety was first presented at the Society for Neuroscience meeting in October 2015 by Dr. Morgan. For updates, visit our website to read the [Akhu Blog](#) and information about Akhu Products.

Safe Harbor Statement

Some statements made here may constitute forward-looking statements under securities laws, based upon our projections, assumptions, and future expectations. Such statements are based on assumptions concerning important factors, risks, and uncertainties that could significantly affect anticipated results in the future and, accordingly, could cause the actual results to differ materially from those expressed in the forward-looking statements. The statements made herein are not guaranties of future performance and actual results may differ materially from those forecasted.

PR courtesy of Online PR Media.

Carnel Morgan, PhD
Akhu Therapeutics, Inc.
979-820-2740
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.